Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

Guselkumab yields durable benefit in biologic-naïve PsA patients
23 Nov 2021
The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.
23 Nov 2021

Finerenone lessens HF burden among patients with CKD, diabetes
22 Nov 2021
bởiJairia Dela Cruz
Treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone helps prevent the incidence of new-onset heart failure (HF) and improve other HF outcomes among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as shown in a secondary analysis of the phase III FIGARO-DKD trial.
22 Nov 2021







